Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05812976 · ClinicalTrials.gov registry record
Novel Index (PIMR) in PAH
A clinical trial, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- 22
- Enrollment target
NCT05812976: Completed study, sponsored by University of California, Los Angeles.
NCT05812976 is a clinical trial that has completed, run by University of California, Los Angeles. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05812976 has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
The chief regulator of resistance in pulmonary arterial hypertension (PAH) is the small arteries. In the heart, the invasive measurement of the resistance of the small arteries has been shownto be safe, easy, reliable, and prognostic. This study is intended to translate prior work in heart arteries to the PAH space and invasively measure the resistance of the small arteries of the lung (pulmonary index of microcirculatory resistance \[PIMR\]) and the coronary artery supplying the right ventricle (acute marginal of the RCA; RV-IMR). Importantly, these measurements will be made during standard of care cardiac catheterizations (right heart catheterization \[RHC\] +/- left heart catheterization). The correlation between these new indices and the standard ones measured during RHC typically used to determine the severity of pulmonary hypertension will be analyzed. In addition, among newly diagnosed patients, the study will evaluate how these indices change 6 months after starting treatment. Finally, the association of these indices with clinical outcomes at 1 year will be assessed. The findings from this study may deliver an immediate impact to patient care by identifying a new metric to help better identify those who may benefit from a more intensive, personalized treatment regimen.
Primary Outcome
The primary outcome is the composite of PAH hospitalization or all-cause mortality at 1 year.
Interventions
- OTHER Pulmonary Index of Microcirculatory Resistance
- OTHER Right Ventricle Index of Microcirculatory Resistance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-02-01 |
| Est. Completion | 2025-04-08 |
What the finished NCT05812976 record still lists
NCT05812976 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Pulmonary Index of Microcirculatory Resistance is the first listed.
NCT05812976 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05812976 about?
NCT05812976 is a clinical study titled "Novel Index (PIMR) in PAH". The chief regulator of resistance in pulmonary arterial hypertension (PAH) is the small arteries. In the heart, the invasive measurement of the resistance of the small arteries has been shownto be safe, easy, reliable, and prognostic. This study is intended to translate prior work in heart arteries ...
What is the current status of trial NCT05812976?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2023-02-01. Estimated completion is 2025-04-08.
What interventions are being tested in trial NCT05812976?
The interventions under investigation include: Pulmonary Index of Microcirculatory Resistance (OTHER), Right Ventricle Index of Microcirculatory Resistance (OTHER).
Who is sponsoring clinical trial NCT05812976?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI